Search Article:

Transfection Reagents Market worth 1.02 Billion USD by 2021

By Dipikajoshi    16 / Apr / 2019    In Category Healthcare

img

This growth can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer. Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.

This market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period. The global transfection reagents and equipment market is segmented on the basis of product, method, application, end user, and region.

Based on product, the transfection reagents and equipment market is categorized into reagents and instruments. In 2016, the reagents segment is estimated to account for the largest share of the market. However, the instruments market is likely to grow at the highest CAGR during the forecast period.

Download the PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139141146


On the basis of method, this market is segmented into biochemical, physical, and viral methods. In 2016, the biochemical method segment is expected to account for the largest share of the market, while the viral method segment is expected to grow at the highest CAGR during the forecast period. The biochemical method segment is further classified into calcium phosphate, lipofection DEAE-dextran, and dendrimer. Whereas, the physical method segment is further divided into electroporation, nucleofection, and others (gengun, sonoporation, magnetofection, and optoinjection).

Based on application, the market is segmented into biomedical research, protein production, and therapeutic delivery. In 2016, the biomedical research segment is estimated to account for the largest share of the market.

On the basis of end user, the transfection reagent market is segmented into academic & research institutes and pharmaceutical & biotechnologies companies. In 2016, the academic & research institutes segment is expected to account for the largest share of the market. On the basis of method, the market is segmented into biochemical, physical, and viral methods. In 2016, the biochemical method segment is expected to account for the largest share of the market, while the viral method segment is expected to grow at the highest CAGR during the forecast period. The biochemical method segment is further classified into calcium phosphate, lipofection DEAE-dextran, and dendrimer. Whereas, the physical method segment is further divided into electroporation, nucleofection, and others (gengun, sonoporation, magnetofection, and optoinjection).

North America is expected to account for the largest share of the transfection reagent market, followed by Europe and Asia-Pacific. The largest share can be attributed to the increase in bio-based drug research, increase in demand for protein therapeutics, and increasing investment for development of biologics in the country. The Asia-Pacific market is slated to grow at the highest CAGR during the forecast period and serve as a major revenue pocket for companies offering transfection reagents and equipment.

Get the Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=139141146


Some of the prominent players in the transfection reagent market include Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands). Polyplus-transfection SA (France), Bio-Rad Laboratories (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte Inc. (U.S.).

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
sales@marketsandmarkets.com

Related Article: